Related Experiment Video
Updated: Jul 18, 2026

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
Published on: July 27, 2022
Methysergide-induced valvular heart disease: a report of 2 cases
Ali M Alizzi1, Ayman H Al-Masri, Mark M Murton
1Department of Cardiothoracic Surgery, Royal Hobart Hospital, Hobart, Tasmania, Australia. alializzi@hotmail.com
Abstract:
Methysergide is a serotonin antagonist and is used as a long-term prophylactic treatment for migraine. Although many patients experience adequate control of migraine episodes, methysergide has been reported to cause retroperitoneal and pleuropulmonary fibrosis. Cardiovascular side effects mainly in the form of valvular fibrosis have been less recognized. We report 2 cases of methysergide-related mitral valve fibrosis.
Related Concept Videos
Mitral Valve Prolapse II: Assessment and Management
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Mitral Regurgitation I: Introduction
Mitral Stenosis III: Medical Management
Mitral Stenosis II: Clinical features and Diagnostic Tests